For professionals in the pharmaceutical and chemical industries, a thorough understanding of product specifications is fundamental to successful procurement and research. This article focuses on the key technical details of 5-Amino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile, CAS number 330792-70-6, a crucial intermediate in the synthesis of the targeted cancer therapy drug, Ibrutinib.

The primary specification for this compound is its purity, typically listed as an assay of ≥98.0%. This high level of purity is critical for its role as a pharmaceutical intermediate, ensuring that downstream reactions proceed efficiently and with minimal unwanted byproducts. The appearance is consistently described as an 'off-white to light yellow powder,' a visual characteristic that aids in initial identification. Manufacturers often provide a comprehensive Certificate of Analysis (CoA) detailing purity, moisture content, residual solvents, and heavy metal limits, which are vital for quality assurance and regulatory compliance.

Beyond purity and appearance, other physical and chemical properties are relevant for handling and processing. These may include a molecular formula of C16H12N4O and a molecular weight of approximately 276.29 g/mol. Information on density and boiling points, while less critical for intermediate procurement, can be useful for process chemists evaluating reaction conditions or scale-up. Storage recommendations, typically a cool, dry, and well-ventilated place, are important for maintaining product stability and shelf life, which is often stated as 2 years.

When sourcing this intermediate, professionals will often search for 'technical data 330792-70-6' or 'specifications for ibrutinib intermediate'. Identifying manufacturers that can consistently meet these technical requirements and provide robust documentation is key. By understanding these specifications, procurement managers and R&D scientists can make informed decisions, secure reliable supply, and ensure the quality of their final Ibrutinib product. Engaging with suppliers who offer this level of transparency is always recommended for critical pharmaceutical raw materials.